Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Fibrinolytic Therapy to Treat ARDS in the Setting of COVID-19 Infection: A Phase 2a Clinical Trial

NCT04357730 is registered in ClinicalTrials.gov with Denver Health and Hospital Authority as lead sponsor.

NCT NCT04357730
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04357730 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Fibrinolytic Therapy to Treat ARDS in the Setting of COVID-19 Infection: A Phase 2a Clinical Trial
Lead sponsor
Denver Health and Hospital Authority
Phase
Phase 2
Overall status
Completed
Start date
May 14, 2020
Completion date
September 30, 2021
Enrollment
50 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

acute respiratory distress syndrome, respiratory failure, severe acute respiratory syndrome